As shown in Fig 4B, there were no trends common between the training and validation sets for effect of age on serum TFPI2 level when each group (benign ovarian tumors, CCC and non-CCC EOCs) was considered. This evidence concerns the gene TFPI2 and ovarian benign neoplasm.